MIM Software (GE HealthCare)
Contouring, image fusion, and dosimetry software (MIM Maestro, SurePlan) for radiotherapy and radioligand therapy, acquired by GE HealthCare in 2024.
Overview
MIM Software, based in Cleveland and acquired by GE HealthCare in 2024, makes contouring, image fusion and dosimetry software, including MIM Maestro and SurePlan, for radiotherapy and radioligand therapy. Its Contour ProtégéAI performs auto-contouring, its PET/CT fusion supports planning, and its personalised dosimetry serves lutetium-177 and yttrium-90 therapies. Nuclide links it to AI auto-contouring and adaptive planning, SPECT and bone scan imaging, and radioligand therapy with beta emitters. Whether personalised dosimetry becomes standard for radioligand therapy, rather than fixed dosing, is the open question its tools are built for. The radioligand therapy page carries the wider evidence.
Similar pages
not linked directly; found by shared links- CompanyTrasis
Shares Lutetium-177 and the tag supporting.
- TechnologyNuclear medicine and total-body PET hardware
Shares SPECT & bone scan, Radioligand therapy (beta emitters) and the tag supporting.
- CompanySHINE Technologies
Shares Lutetium-177 and the tag supporting.
- CompanyEckert & Ziegler
Shares Lutetium-177 and the tag supporting.
- CompanyNorthStar Medical Radioisotopes
Shares Lutetium-177 and the tag supporting.
- TechnologyRadiopharmacy and cyclotron networks
Shares Radioligand therapy (beta emitters), Lutetium-177 and the tag supporting.
- TechnologyMedical cyclotrons, hot cells, and synthesis modules
Shares Radioligand therapy (beta emitters) and the tag supporting.
- TechnologyTherapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)
Shares Radioligand therapy (beta emitters), Lutetium-177 and the tag supporting.